Journal article
Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: Potential as EphA3-specific tumor-targeting reagents
C Vearing, FT Lee, S Wimmer-Kleikamp, V Spirkoska, C To, C Stylianou, M Spanevello, M Brechbiel, AW Boyd, AM Scott, M Lackmann
Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2005
Abstract
The Eph receptor tyrosine kinases and their membrane-bound ephrin ligands form a unique cell-cell contact-mediated system for controlling cell localization and organization. Their high expression in a wide variety of human tumors indicates a role in tumor progression, and relatively low Eph and ephrin levels in normal tissues make these proteins potential targets for anticancer therapies. The monoclonal antibody IIIA4, previously used to isolate EphA3, binds with subnanomolar affinity to a conformation-specific epitope within the ephrin-binding domain that is closely adjacent to the "low-affinity" ephrin-A5 heterotetramerization site. We show that similar to ephrin-A5, preclustered IIIA4 eff..
View full abstractGrants
Awarded by National Cancer Institute